Table 3.
Summary of results from studies of first-line therapy with octreotide LAR in patients with acromegaly
| Reference | No of pts | Duration of treatment | Patients meeting criterion for GH control (%) | Patients with IGF-1 normalization (%) | Mean tumor shrinkage (%) | % of patients with significant tumor shrinkage (definition of significant) |
|---|---|---|---|---|---|---|
| Colao et al 2001 [101] | 15 | 12-24 months | 73 | 53 | 53 | 80 (>20%) |
| Amato et al 2002 [99] | 8 | 24 months | 50 | 50 | 34.8 | 100 (>10%) |
| Ayuk et al 2004 [100] | 25 | 48 weeks | 62 | 64 | NR | NR |
| Jallad et al 2005 [105] | 28 | 6-24 months | NR | 43 | NR | 76 (>25%) |
| Colao et al 2006 [102] | 34 | 6 months | 61 | 45.5 | 54 (median) | 74 (>30%) |
| Cozzi et al 2006 [104] | 67 | 6-108 months | 69 | 70 | 62 | 82 (>25%) |
| Mercado et al 2007 [106] | 68 | 48 weeks | 44 | 34 | 39 | 75 (>20%) |
| Colao et al 2007 [103] | 56 | 24 months | 86 | 84 | 68 | NR |
| Colao et al 2008 [127] | 67 | 12 months | 52 | 58 | 49 | 85 (>25%) |
| Colao et al 2008 [128] | 40 | 48 weeks | NR | NR | 35 | 73 (>20%) |
NR = not reported